Kodiak Sciences, a Palo Alto, CA, eye drug developer, has appointed Jason Ehrlich to serve as chief medical officer and chief development officer. Ehrlich comes to Kodiak from Roche subsidiary, Genentech, where he was global head, clinical ophthalmology. Recently, Kodiak filed for an IPO to finance clinical trials testing its lead drug, KSI-301, in patients who have the “wet” form of age-related macular degeneration.
Xconomy Insight · Special Report
Industry experts explain what it takes to launch a new biotech company
Sponsored · Whitepaper
Knowing the volume of procedures and growth trends by site of care can allow you to understand the market demand for your product
IBM Watson
Sponsored · Video
A Fireside Chat with Medpace's Regulatory Affairs Director David Horton
Medpace
